Dry Age-Related Macular Degeneration Clinical Trials

8 recruitingLast updated: May 21, 2026

There are 8 actively recruiting dry age-related macular degeneration clinical trials across 4 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Beverly Hills, California, United States, Bangkok, Dusit, Thailand, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Dry Age-Related Macular Degeneration Trials at a Glance

8 actively recruiting trials for dry age-related macular degeneration are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Beverly Hills, Bangkok, and Bethesda. Lead sponsors running dry age-related macular degeneration studies include Fondazione Policlinico Universitario Agostino Gemelli IRCCS, LumiThera, Inc., and Bionic Sight LLC.

Browse dry age-related macular degeneration trials by phase

About Dry Age-Related Macular Degeneration Clinical Trials

Looking for clinical trials for Dry Age-Related Macular Degeneration? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dry Age-Related Macular Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dry Age-Related Macular Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Geographic AtrophyDry Age-Related Macular Degeneration
Regenerative Patch Technologies, LLC24 enrolled5 locationsNCT06557460
Recruiting
Phase 1Phase 2

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Geographic AtrophyDry Age-Related Macular Degeneration
National Eye Institute (NEI)20 enrolled2 locationsNCT04339764
Recruiting
Phase 1Phase 2

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775
Recruiting
Phase 1Phase 2

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Dry Age-Related Macular Degeneration
Luxa Biotechnology, LLC18 enrolled3 locationsNCT04627428
Recruiting
Not Applicable

Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma

Dry Age-Related Macular Degeneration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS36 enrolled1 locationNCT05706896
Recruiting
Not Applicable

Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.

Dry Age-Related Macular Degeneration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS36 enrolled1 locationNCT06536062
Recruiting

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)

Dry Age-Related Macular Degeneration
LumiThera, Inc.500 enrolled1 locationNCT06351605
Recruiting
Phase 3

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

Dry Age-Related Macular Degeneration
Navamindradhiraj University174 enrolled1 locationNCT06165068